IPH5201 Biosimilar - Research Grade

Human

CD39

>1mg/ml

Human IgG1 Kappa

CHO Cells

Perenostobart Biosimilar - Research Grade (ICH5265), Eurestobart Biosimilar - Research Grade (ICH5537)

https://www.imgt.org/mAb-DB/

ICH3002

P49961

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CD39 antibody IPH5201, supplied for research use only. It is a human IgG1 kappa protein built to engage human CD39 (ENTPD1) and is not the clinical drug, nor is it intended for human or veterinary use. As a research-grade biosimilar, it is useful as a defined, reproducible tool for interrogating the CD39-adenosine axis in vitro and in preclinical settings: as a positive binding reagent, an isotype-matched functional control, a benchmarking standard against internally generated antibodies, and a reference for enzyme-blocking, neutralisation, and antibody-development workflows (for example ADCC characterisation or ADC feasibility studies). It is offered at low endotoxin levels (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, screening cascades, and preclinical model work where lot consistency and scale matter. Because it targets human CD39, its primary value is in human cell and human-target biochemical systems rather than as a therapeutic. Guidance for ichorbio to review. CD39, encoded by ENTPD1 (UniProt P49961), is a plasma-membrane ectonucleoside triphosphate diphosphohydrolase and the rate-limiting enzyme of the extracellular adenosinergic pathway. It hydrolyses pro-inflammatory extracellular ATP and ADP to AMP, which CD73 then converts to immunosuppressive adenosine. By depleting immunostimulatory ATP and feeding adenosine production, CD39 shifts the tumour and inflammatory microenvironment toward immune tolerance. It is expressed on regulatory T cells, subsets of effector and exhausted T cells, B cells, myeloid cells, endothelium, and many tumour cells, and is frequently studied as a prognostic and pharmacodynamic marker. Enzymatic blockade of CD39 raises local ATP and lowers adenosine, promoting dendritic-cell and inflammasome activation and relieving adenosine-mediated suppression, which is why CD39 is pursued as a target complementary to CD73 and PD-1/PD-L1 checkpoint blockade.

ATP diphosphohydrolase, ATP-DPH, ATPDase, Ecto-ATP diphosphohydrolase 1, Ecto-ATPDase 1, Ecto-ATPase 1, Ecto-apyrase, Lymphoid cell activation antigen, Nucleoside triphosphate diphosphohydrolase 1, NTPDase1, Ectonucleoside triphosphate diphosphohydrolase

Detects CD39

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.